Key result
Proteomic analysis of platelets from aged mice identified 308 altered proteins, highlighting β2GP1, AGP2, and Rab11a as potential antithrombotic drug targets.
Why the study?
Thromboembolism prevalence and mortality are higher in the elderly, but evidence confirming that antithrombotic agents are suitable for this population is lacking.
Proteomic analysis of aged mouse platelets identified β2GP1, AGP2, and Rab11a as potential novel targets for age-specific antiplatelet therapy.
Nominates β2GP1, AGP2, and Rab11a as antithrombotic candidates in aging; leaves open validation in human platelets and thrombosis.
Aging is a growing problem worldwide, and the prevalence and mortality of arterial and venous thromboembolism (VTE) are higher in the elderly than in the young population. To address this issue, various anticoagulants have been used. However, no evidence can confirm that antithrombotic agents are suitable for the elderly. Therefore, this study aims to investigate the platelet proteome of aged mice and identify antithrombotic drug targets specific to the elderly. Based on the proteome analysis of platelets from aged mice, 308 increased or decreased proteins were identified. Among these proteins, three targets were selected as potential antithrombotic drug targets. These targets are membrane proteins or related to platelet function and include beta-2-glycoprotein 1 (β2GP1, ApolipoproteinH (ApoH)), alpha-1-acid glycoprotein2 (AGP2, Orosomucoid-2 (Orm2)), and Ras-related protein (Rab11a).
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied Arterial and venous thromboembolism. Proteomic analysis was evaluated on Identification of potential antithrombotic drug targets. Proteomic analysis of platelets from aged mice identified 308 altered proteins, highlighting β2GP1, AGP2, and Rab11a as potential antithrombotic drug targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: